Display options
Cite
Ahearn TU, Zhang H, Michailidou K, et al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Res. 2022;24(1):2doi: 10.1186/s13058-021-01484-x.
Ahearn, T. U., Zhang, H., Michailidou, K., Milne, R. L., Bolla, M. K., Dennis, J., Dunning, A. M., Lush, M., Wang, Q., Andrulis, I. L., Anton-Culver, H., Arndt, V., Aronson, K. J., Auer, P. L., Augustinsson, A., Baten, A., Becher, H., Behrens, S., Benitez, J., Bermisheva, M., Blomqvist, C., Bojesen, S. E., Bonanni, B., Børresen-Dale, A. L., Brauch, H., Brenner, H., Brooks-Wilson, A., Brüning, T., Burwinkel, B., Buys, S. S., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Chenevix-Trench, G., Clarke, C. L., Collée, J. M., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Dörk, T., Dwek, M., Eccles, D. M., Evans, D. G., Fasching, P. A., Figueroa, J., Floris, G., Gago-Dominguez, M., Gapstur, S. M., García-Sáenz, J. A., Gaudet, M. M., Giles, G. G., Goldberg, M. S., González-Neira, A., Alnæs, G. I. G., Grip, M., Guénel, P., Haiman, C. A., Hall, P., Hamann, U., Harkness, E. F., Heemskerk-Gerritsen, B. A. M., Holleczek, B., Hollestelle, A., Hooning, M. J., Hoover, R. N., Hopper, J. L., Howell, A., Jakimovska, M., Jakubowska, A., John, E. M., Jones, M. E., Jung, A., Kaaks, R., Kauppila, S., Keeman, R., Khusnutdinova, E., Kitahara, C. M., Ko, Y. D., Koutros, S., Kristensen, V. N., Krüger, U., Kubelka-Sabit, K., Kurian, A. W., Kyriacou, K., Lambrechts, D., Lee, D. G., Lindblom, A., Linet, M., Lissowska, J., Llaneza, A., Lo, W. Y., MacInnis, R. J., Mannermaa, A., Manoochehri, M., Margolin, S., Martinez, M. E., McLean, C., Meindl, A., Menon, U., Nevanlinna, H., Newman, W. G., Nodora, J., Offit, K., Olsson, H., Orr, N., Park-Simon, T. W., Patel, A. V., Peto, J., Pita, G., Plaseska-Karanfilska, D., Prentice, R., Punie, K., Pylkäs, K., Radice, P., Rennert, G., Romero, A., Rüdiger, T., Saloustros, E., Sampson, S., Sandler, D. P., Sawyer, E. J., Schmutzler, R. K., Schoemaker, M. J., Schöttker, B., Sherman, M. E., Shu, X. O., Smichkoska, S., Southey, M. C., Spinelli, J. J., Swerdlow, A. J., Tamimi, R. M., Tapper, W. J., Taylor, J. A., Teras, L. R., Terry, M. B., Torres, D., Troester, M. A., Vachon, C. M., van Deurzen, C. H. M., van Veen, E. M., Wagner, P., Weinberg, C. R., Wendt, C., Wesseling, J., Winqvist, R., Wolk, A., Yang, X. R., Zheng, W., Couch, F. J., Simard, J., Kraft, P., Easton, D. F., Pharoah, P. D. P., Schmidt, M. K., García-Closas, M., & Chatterjee, N. (2022). Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast cancer research : BCR, 24(1), 2. https://doi.org/10.1186/s13058-021-01484-x
Ahearn, Thomas U, et al. "Common variants in breast cancer risk loci predispose to distinct tumor subtypes." Breast cancer research : BCR vol. 24,1 (2022): 2. doi: https://doi.org/10.1186/s13058-021-01484-x
Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Augustinsson A, Baten A, Becher H, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Brenner H, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Clarke CL, Collée JM, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dwek M, Eccles DM, Evans DG, Fasching PA, Figueroa J, Floris G, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, González-Neira A, Alnæs GIG, Grip M, Guénel P, Haiman CA, Hall P, Hamann U, Harkness EF, Heemskerk-Gerritsen BAM, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Jakimovska M, Jakubowska A, John EM, Jones ME, Jung A, Kaaks R, Kauppila S, Keeman R, Khusnutdinova E, Kitahara CM, Ko YD, Koutros S, Kristensen VN, Krüger U, Kubelka-Sabit K, Kurian AW, Kyriacou K, Lambrechts D, Lee DG, Lindblom A, Linet M, Lissowska J, Llaneza A, Lo WY, MacInnis RJ, Mannermaa A, Manoochehri M, Margolin S, Martinez ME, McLean C, Meindl A, Menon U, Nevanlinna H, Newman WG, Nodora J, Offit K, Olsson H, Orr N, Park-Simon TW, Patel AV, Peto J, Pita G, Plaseska-Karanfilska D, Prentice R, Punie K, Pylkäs K, Radice P, Rennert G, Romero A, Rüdiger T, Saloustros E, Sampson S, Sandler DP, Sawyer EJ, Schmutzler RK, Schoemaker MJ, Schöttker B, Sherman ME, Shu XO, Smichkoska S, Southey MC, Spinelli JJ, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Teras LR, Terry MB, Torres D, Troester MA, Vachon CM, van Deurzen CHM, van Veen EM, Wagner P, Weinberg CR, Wendt C, Wesseling J, Winqvist R, Wolk A, Yang XR, Zheng W, Couch FJ, Simard J, Kraft P, Easton DF, Pharoah PDP, Schmidt MK, García-Closas M, Chatterjee N. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Res. 2022 Jan 04;24(1):2. doi: 10.1186/s13058-021-01484-x. PMID: 34983606.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer Res. 2022 Jan 04;24(1):2. doi: 10.1186/s13058-021-01484-x.

Common variants in breast cancer risk loci predispose to distinct tumor subtypes.

Breast cancer research : BCR

Thomas U Ahearn, Haoyu Zhang, Kyriaki Michailidou, Roger L Milne, Manjeet K Bolla, Joe Dennis, Alison M Dunning, Michael Lush, Qin Wang, Irene L Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J Aronson, Paul L Auer, Annelie Augustinsson, Adinda Baten, Heiko Becher, Sabine Behrens, Javier Benitez, Marina Bermisheva, Carl Blomqvist, Stig E Bojesen, Bernardo Bonanni, Anne-Lise Børresen-Dale, Hiltrud Brauch, Hermann Brenner, Angela Brooks-Wilson, Thomas Brüning, Barbara Burwinkel, Saundra S Buys, Federico Canzian, Jose E Castelao, Jenny Chang-Claude, Stephen J Chanock, Georgia Chenevix-Trench, Christine L Clarke, J Margriet Collée, Angela Cox, Simon S Cross, Kamila Czene, Mary B Daly, Peter Devilee, Thilo Dörk, Miriam Dwek, Diana M Eccles, D Gareth Evans, Peter A Fasching, Jonine Figueroa, Giuseppe Floris, Manuela Gago-Dominguez, Susan M Gapstur, José A García-Sáenz, Mia M Gaudet, Graham G Giles, Mark S Goldberg, Anna González-Neira, Grethe I Grenaker Alnæs, Mervi Grip, Pascal Guénel, Christopher A Haiman, Per Hall, Ute Hamann, Elaine F Harkness, Bernadette A M Heemskerk-Gerritsen, Bernd Holleczek, Antoinette Hollestelle, Maartje J Hooning, Robert N Hoover, John L Hopper, Anthony Howell, Milena Jakimovska, Anna Jakubowska, Esther M John, Michael E Jones, Audrey Jung, Rudolf Kaaks, Saila Kauppila, Renske Keeman, Elza Khusnutdinova, Cari M Kitahara, Yon-Dschun Ko, Stella Koutros, Vessela N Kristensen, Ute Krüger, Katerina Kubelka-Sabit, Allison W Kurian, Kyriacos Kyriacou, Diether Lambrechts, Derrick G Lee, Annika Lindblom, Martha Linet, Jolanta Lissowska, Ana Llaneza, Wing-Yee Lo, Robert J MacInnis, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Maria Elena Martinez, Catriona McLean, Alfons Meindl, Usha Menon, Heli Nevanlinna, William G Newman, Jesse Nodora, Kenneth Offit, Håkan Olsson, Nick Orr, Tjoung-Won Park-Simon, Alpa V Patel, Julian Peto, Guillermo Pita, Dijana Plaseska-Karanfilska, Ross Prentice, Kevin Punie, Katri Pylkäs, Paolo Radice, Gad Rennert, Atocha Romero, Thomas Rüdiger, Emmanouil Saloustros, Sarah Sampson, Dale P Sandler, Elinor J Sawyer, Rita K Schmutzler, Minouk J Schoemaker, Ben Schöttker, Mark E Sherman, Xiao-Ou Shu, Snezhana Smichkoska, Melissa C Southey, John J Spinelli, Anthony J Swerdlow, Rulla M Tamimi, William J Tapper, Jack A Taylor, Lauren R Teras, Mary Beth Terry, Diana Torres, Melissa A Troester, Celine M Vachon, Carolien H M van Deurzen, Elke M van Veen, Philippe Wagner, Clarice R Weinberg, Camilla Wendt, Jelle Wesseling, Robert Winqvist, Alicja Wolk, Xiaohong R Yang, Wei Zheng, Fergus J Couch, Jacques Simard, Peter Kraft, Douglas F Easton, Paul D P Pharoah, Marjanka K Schmidt, Montserrat García-Closas, Nilanjan Chatterjee

Affiliations

  1. Division of Cancer Epidemiology and GeneticsDepartment of Health and Human Services, Medical Center Drive, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
  2. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  3. Institute of Neurology & Genetics, Biostatistics Unit, Nicosia, Cyprus.
  4. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  5. Cyprus School of Molecular Medicine, Institute of Neurology & Genetics, Nicosia, Cyprus.
  6. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  7. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  8. Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
  9. Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  10. Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  11. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  12. Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  13. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  14. Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  15. Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  16. Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, USA.
  17. Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.
  18. Leuven Multidisciplinary Breast Center, Department of Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  19. Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  20. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  21. Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  22. Biomedical Network On Rare Diseases (CIBERER), Madrid, Spain.
  23. Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.
  24. Saint Petersburg State University, Saint-Petersburg, Russia.
  25. Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  26. Department of Oncology, Örebro University Hospital, Örebro, Sweden.
  27. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  28. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  29. Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  30. Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  31. Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
  32. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  33. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  34. iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany.
  35. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.
  36. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  37. Division of Preventive Oncology, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  38. Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
  39. Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
  40. Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute, Ruhr University Bochum (IPA), Bochum, Germany.
  41. Molecular Epidemiology Group, German Cancer Research Center (DKFZ), C080, Heidelberg, Germany.
  42. Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.
  43. Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT, USA.
  44. Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  45. Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
  46. Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  47. Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  48. Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia.
  49. Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  50. Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SInFoNiA), University of Sheffield, Sheffield, UK.
  51. Department of Neuroscience, Academic Unit of Pathology, University of Sheffield, Sheffield, UK.
  52. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  53. Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
  54. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  55. Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
  56. Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  57. School of Life Sciences, University of Westminster, London, UK.
  58. Faculty of Medicine, University of Southampton, Southampton, UK.
  59. North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  60. Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  61. Department of Gynecology and Obstetrics Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  62. Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
  63. Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK.
  64. Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
  65. Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
  66. Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA, USA.
  67. Medical Oncology Department, Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
  68. Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University, Montréal, QC, Canada.
  69. Department of Medicine, McGill University, Montréal, QC, Canada.
  70. Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland.
  71. Center for Research in Epidemiology and Population Health (CESP), Team Exposome and Heredity, INSERM, University Paris-Saclay, Villejuif, France.
  72. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  73. Department of Oncology, Södersjukhuset, Stockholm, Sweden.
  74. Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  75. Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  76. Nightingale & Genesis Prevention Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
  77. NIHR Manchester Biomedical Research Unit, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  78. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  79. Saarland Cancer Registry, Saarbrücken, Germany.
  80. Division of Cancer Sciences, University of Manchester, Manchester, UK.
  81. Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov", MASA, Skopje, Republic of North Macedonia.
  82. Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  83. Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland.
  84. Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.
  85. Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  86. Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  87. Department of Pathology, Oulu University Hospital, University of Oulu, Oulu, Finland.
  88. Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  89. Department of Genetics and Fundamental Medicine, Bashkir State University, Ufa, Russia.
  90. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  91. Department of Internal Medicine, Johanniter Kliniken Bonn, Johanniter Krankenhaus, Bonn, Germany.
  92. Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway.
  93. Department of Histopathology and Cytology, Clinical Hospital Acibadem Sistina, Skopje, Republic of North Macedonia.
  94. Cancer Genetics, Therapeutics and Ultrastructural Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  95. Laboratory for Translational Genetics, Department of Human Genetics, University of Leuven, Leuven, Belgium.
  96. VIB Center for Cancer Biology, Leuven, Belgium.
  97. Cancer Control Research, BC Cancer, Vancouver, BC, Canada.
  98. Department of Mathematics and Statistics, St. Francis Xavier University, Antigonish, NS, Canada.
  99. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  100. Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
  101. Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  102. General and Gastroenterology Surgery Service, Hospital Universitario Central de Asturias, Oviedo, Spain.
  103. University of Tübingen, Tübingen, Germany.
  104. Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
  105. Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
  106. Biobank of Eastern Finland, Kuopio University Hospital, Kuopio, Finland.
  107. Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset Stockholm, Sweden.
  108. Anatomical Pathology, The Alfred Hospital, Melbourne, VIC, Australia.
  109. Department of Gynecology and Obstetrics, University of Munich, Campus Großhadern, Munich, Germany.
  110. Institute of Clinical Trials & Methodology, University College London, London, UK.
  111. Department of Obstetrics and Gynecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  112. Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA.
  113. Clinical Genetics Research Lab, Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  114. Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Ireland, UK.
  115. Department of Non-Communicable Disease Epidemiology, School of Hygiene and Tropical Medicine, London, UK.
  116. Human Genotyping-CEGEN Unit, Human Cancer Genetic Program, Spanish National Cancer Research Centre, Madrid, Spain.
  117. Department of General Medical Oncology and Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  118. Laboratory of Cancer Genetics and Tumor Biology, Cancer and Translational Medicine Research Unit, University of Oulu, Biocenter Oulu, Oulu, Finland.
  119. Laboratory of Cancer Genetics and Tumor Biology, Northern Finland Laboratory Centre Oulu, Oulu, Finland.
  120. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori (INT), Milan, Italy.
  121. Technion Faculty of Medicine, Clalit National Cancer Control Center, Carmel Medical Center, Haifa, Israel.
  122. Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  123. Institute of Pathology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.
  124. Department of Oncology, University Hospital of Larissa, Larissa, Greece.
  125. Prevent Breast Cancer Centre and Nightingale Breast Screening Centre, Manchester University NHS Foundation Trust, Manchester, UK.
  126. Epidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
  127. School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy's Campus, King's College London, London, UK.
  128. Center for Integrated Oncology (CIO), Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  129. Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  130. Center for Familial Breast and Ovarian Cancer, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.
  131. Network Aging Research, University of Heidelberg, Heidelberg, Germany.
  132. Department of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
  133. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
  134. Medical Faculty, Ss. Cyril and Methodius University in Skopje, University Clinic of Radiotherapy and Oncology, Skopje, Republic of North Macedonia.
  135. Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia.
  136. Population Oncology, BC Cancer, Vancouver, BC, Canada.
  137. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
  138. Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
  139. Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
  140. Epigenetic and Stem Cell Biology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
  141. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
  142. Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
  143. Department of Epidemiology, Gillings School of Global Public Health and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  144. Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
  145. Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  146. Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA.
  147. Department of Pathology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  148. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  149. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  150. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  151. Genomics Center, Department of Molecular Medicine, Centre Hospitalier Universitaire de Québec, Université Laval Research Center, Université Laval, Québec City, QC, Canada.
  152. Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  153. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  154. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute - Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  155. Division of Cancer Epidemiology and GeneticsDepartment of Health and Human Services, Medical Center Drive, National Cancer Institute, National Institutes of Health, Rockville, MD, USA. [email protected].
  156. Department of Biostatistics, Bloomberg School of Public Health, John Hopkins University, Baltimore, MD, USA.
  157. Department of Oncology, School of Medicine, John Hopkins University, Baltimore, MD, USA.

PMID: 34983606 DOI: 10.1186/s13058-021-01484-x

Abstract

BACKGROUND: Genome-wide association studies (GWAS) have identified multiple common breast cancer susceptibility variants. Many of these variants have differential associations by estrogen receptor (ER) status, but how these variants relate with other tumor features and intrinsic molecular subtypes is unclear.

METHODS: Among 106,571 invasive breast cancer cases and 95,762 controls of European ancestry with data on 173 breast cancer variants identified in previous GWAS, we used novel two-stage polytomous logistic regression models to evaluate variants in relation to multiple tumor features (ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and grade) adjusting for each other, and to intrinsic-like subtypes.

RESULTS: Eighty-five of 173 variants were associated with at least one tumor feature (false discovery rate < 5%), most commonly ER and grade, followed by PR and HER2. Models for intrinsic-like subtypes found nearly all of these variants (83 of 85) associated at p < 0.05 with risk for at least one luminal-like subtype, and approximately half (41 of 85) of the variants were associated with risk of at least one non-luminal subtype, including 32 variants associated with triple-negative (TN) disease. Ten variants were associated with risk of all subtypes in different magnitude. Five variants were associated with risk of luminal A-like and TN subtypes in opposite directions.

CONCLUSION: This report demonstrates a high level of complexity in the etiology heterogeneity of breast cancer susceptibility variants and can inform investigations of subtype-specific risk prediction.

© 2021. The Author(s).

Keywords: Breast cancer; Common breast cancer susceptibility variants; Etiologic heterogeneity; Genetic predisposition

References

  1. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. - PubMed
  2. Curigliano G, Burstein HJ, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ et al: De-escalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017, 28(8):1700–1712. - PubMed
  3. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ. Panel m: personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206–23. - PubMed
  4. Barnard ME, Boeke CE, Tamimi RM. Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015;1856(1):73–85. - PubMed
  5. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103(3):250–63. - PubMed
  6. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, Lemacon A, Soucy P, Glubb D, Rostamianfar A, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92–4. - PubMed
  7. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindstrom S, Hui S, Lemacon A, Soucy P, Dennis J, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017;49(12):1767–78. - PubMed
  8. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392–8. - PubMed
  9. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, et al. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016;48(4):374–86. - PubMed
  10. Milne RL, Goode EL, Garcia-Closas M, Couch FJ, Severi G, Hein R, Fredericksen Z, Malats N, Zamora MP, Arias Perez JI, et al. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol Biomark Prevent. 2011;20(10):2222–31. - PubMed
  11. Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20(23):4693–706. - PubMed
  12. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, et al. Fine-mapping identifies two additional breast cancer susceptibility loci at 9q312. Hum Mol Genet. 2015;24(10):2966–84. - PubMed
  13. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20(16):3289–303. - PubMed
  14. Zhang H, Zhao N, Ahearn TU, Wheeler W, García-Closas M, Chatterjee N: A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics. Biostatistics 2020. - PubMed
  15. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O’Mara TA, Zhao N, Bolla MK, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572–81. - PubMed
  16. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020;52(1):56–73. - PubMed
  17. Dempster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via em algorithm. J Roy Stat Soc B Met. 1977;39(1):1–38. - PubMed
  18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57(1):289–300. - PubMed
  19. Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847–9. - PubMed
  20. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51. - PubMed
  21. Mesa-Eguiagaray I, Wild SH, Rosenberg PS, Bird SM, Brewster DH, Hall PS, Cameron DA, Morrison D, Figueroa JD. Distinct temporal trends in breast cancer incidence from 1997 to 2016 by molecular subtypes: a population-based study of Scottish cancer registry data. Br J Cancer. 2020;123(5):852–9. - PubMed
  22. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087–93. - PubMed
  23. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870–4. - PubMed
  24. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007;39(7):865–9. - PubMed
  25. Li J, Williams BL, Haire LF, Goldberg M, Wilker E, Durocher D, Yaffe MB, Jackson SP, Smerdon SJ. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell. 2002;9(5):1045–54. - PubMed
  26. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017;49(7):1126–32. - PubMed
  27. Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, Zong X, Laplana M, Wei Y, Han Y, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736–41. - PubMed
  28. Obazee O, Archibugi L, Andriulli A, Soucek P, Malecka-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, et al. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Int J Cancer. 2019;145(3):686–93. - PubMed
  29. Rudd MF, Sellick GS, Webb EL, Catovsky D, Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood. 2006;108(2):638–44. - PubMed
  30. Liu C, Wang QS, Wang YJ. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13(5):2051–5. - PubMed
  31. Lesseur C, Ferreiro-Iglesias A, McKay JD, Bosse Y, Johansson M, Gaborieau V, Landi MT, Christiani DC, Caporaso NC, Bojesen SE et al: Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. PLoS genetics 2021, 17(3):e1009254. - PubMed
  32. Ovarian Cancer Association Consortium - Results lookup by region [ http://ocac.ccge.medschl.cam.ac.uk/data-projects/results-lookup-by-region/ ] - PubMed
  33. Fang J, Jia J, Makowski M, Xu M, Wang Z, Zhang T, Hoskins JW, Choi J, Han Y, Zhang M, et al. Functional characterization of a multi-cancer risk locus on chr5p1533 reveals regulation of TERT by ZNF148. Nat Commun. 2017;8(1):15034. - PubMed
  34. Kim-Hellmuth S, Aguet F, Oliva M, Munoz-Aguirre M, Kasela S, Wucher V, Castel SE, Hamel AR, Vinuela A, Roberts AL et al: Cell type-specific genetic regulation of gene expression across human tissues. Science 2020, 369(6509). - PubMed
  35. Li X, Zou W, Liu M, Cao W, Jiang Y, An G, Wang Y, Huang S, Zhao X. Association of multiple genetic variants with breast cancer susceptibility in the Han Chinese population. Oncotarget. 2016;7(51):85483–91. - PubMed
  36. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61. - PubMed
  37. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, et al. Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression. Am J Hum Genet. 2015;97(1):22–34. - PubMed
  38. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10. - PubMed
  39. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223(2):307–17. - PubMed
  40. Schymik B, Buerger H, Kramer A, Voss U, van der Groep P, Meinerz W, van Diest PJ, Korsching E. Is there “progression through grade” in ductal invasive breast cancer? Breast Cancer Res Treat. 2012;135(3):693–703. - PubMed
  41. Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Can Res. 1999;59(7):1433–6. - PubMed
  42. Rajakariar R, Walker RA. Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer. 1995;71(1):150–4. - PubMed
  43. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, et al. A polymorphic stop codon in BRCA2. Nat Genet. 1996;14(3):253–4. - PubMed
  44. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S et al, BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2016, 108(2). - PubMed
  45. Darabi H, Beesley J, Droit A, Kar S, Nord S, Moradi Marjaneh M, Soucy P, Michailidou K, Ghoussaini M, Fues Wahl H, et al. Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Sci Rep. 2016;6:32512. - PubMed
  46. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373–80. - PubMed
  47. Little RJA, Rubin DB: Statistical analysis with missing data. In: Wiley series in probability and statistics. Third edition edn. Hoboken, NJ: Wiley,; 2019: 1 online resource. - PubMed
  48. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet. 2019;104(1):21–34. - PubMed

Publication Types

Grant support